Premium
Challenges and Opportunities for Local and Systemic Delivery of siRNA and Antisense Oligonucleotides
Author(s) -
SeppLorenzino L,
Ruddy MK
Publication year - 2008
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2008.174
Subject(s) - oligonucleotide , computational biology , pharmaceutical technology , pharmacology , computer science , medicine , biology , chemistry , genetics , dna , chromatography
The discovery and application of oligonucleotide technologies have already changed our fundamental understanding of biology and created a wealth of possibilities for development of new therapeutic entities. A major advantage of oligonucleotide‐based technologies is the potential to develop specific therapeutic antagonists to approach targets previously considered undruggable with a traditional small‐molecule approach. Although there is great potential for this technology in the development of new therapeutic agents, there are significant issues to be overcome before this technology can be readily translated into therapeutic use. Clinical Pharmacology & Therapeutics (2008); 84 , 5, 628–632 doi: 10.1038/clpt.2008.174